Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
September 10, 2026
Rezera has aligned with regulators on trial design of Phase 3 study of ruvonoflast in peripheral artery disease (PAD), expected to initiate in 1H of